Therapy Areas: Diabetes
Active Biotech granted US patent for laquinimod in eye disorders
24 October 2022 -

Swedish biotechnology company Active Biotech AB (STO: ACTI) said on Monday that the US Patent Office (USPTO) has decided to grant Active Biotech's patent related to use of laquinimod as a treatment for eye diseases associated with excessive vascularisation.

The patent is expected to be issued on 25 October 2022 under patent number 11,478,465, providing protection and market exclusivity in this field of use until 2040.

Specifically, Active Biotech's new patent covers the medical use of des-ethyl laquinimod for treatment of sight-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularisation, choroidal neovascularisation, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy.

Active Biotech already has a European patent for the use of laquinimod in eye diseases associated with excessive vascularisation.

Login
Username:

Password: